Program
MVA strain monkeypox attenuated live vaccine (low dose)
Also written as “MVA strain monkeypox attenuated live vaccine (high dose)”.
Its studies are mostly in Mpox, Monkeypox, led by Sinopharm.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinopharm | 11 open or running | phase 1since Jan 8, 2025 | Jan 8, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2025First study: phase 1 study in Mpox, MonkeypoxFirst studyNCT06771479 · 120 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“MVA strain monkeypox attenuated live vaccine (low dose)”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06771479Mpox, Monkeypox · China | 1 | Recruiting | Jan 30, 2026 | 120 |
How it is read
Names in the registry
- “MVA strain monkeypox attenuated live vaccine (low dose)”, 1 entry
- “MVA strain monkeypox attenuated live vaccine (high dose)”, 1 entry
Conditions, from the studies’ own filings
- Mpox, Monkeypox, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.